Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Prostatic Neoplasms 8Lung Neoplasms 8Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Multiple Myeloma 5Melanoma 5Carcinoma, Non-Small-Cell Lung 5Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Glioblastoma 4Colorectal Neoplasms 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Glioma 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Burkitt Lymphoma 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Neuroblastoma 2Meningioma 2Lymphoma, B-Cell 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Merkel Cell 2Astrocytoma 2Adenocarcinoma of Lung 2

Interventions

Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Bevacizumab 1ASTX-660 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Platinum-Refractory Fallopian Tube Carcinoma × Magnetic Resonance Spectroscopy × Clear all
NCT06393751 2025-06-03

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
GynecologicSarcoma

Platinum-Refractory Fallopian Tube Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡